Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Amos Katz, Matthew T. Wheeler et al.|The Lancet|2020Cited by 1.2k
Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy ― The HORIZON-HCM Study ―Hiroaki Kitaoka, Chisato Izumi, Masaki Ieda et al.|Circulation Journal|2024Cited by 23
Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Preserved Ejection Fraction: Cardiac Structure and Function, Clinical Outcomes, and Response to Sacubitril/Valsartan in PARAGON-HFMats Christian Højbjerg Lassen, Muthiah Vaduganathan, John W. Ostrominski et al.|European Journal of Heart Failure|2024Cited by 22
Prognostic Significance of Nutritional Scores in Patients With Heart Failure: Insights From the PARAGON‐HF TrialHenri Lu, Hicham Skali, Brian Claggett et al.|Journal of the American Heart Association|2025Cited by 12